Full-Time

Executive Director

Portfolio Management, Rare Disease

Confirmed live in the last 24 hours

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

Biotechnology
Healthcare

Compensation Overview

$253k - $316.5kAnnually

+ Bonus + Equity Awards

Senior, Expert

San Diego, CA, USA

Hybrid model requires in-office presence three days per week.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in life science or related field; Advanced degree preferred.
  • Targeting 15 years of progressively responsible, relevant experience focusing on program management with 10 years in a leadership role which includes experience managing cross-functional project teams.
  • Strong understanding of the drug development process from preclinical pharmacology through to regulatory approval and the principles, concepts, practices, and standards of pharmaceutical program management.
  • Executive presence and communication skills required.
  • Excellent knowledge of project management discipline and its application to drug development required to deliver time, cost, quality and risk management to teams.
  • Advanced meeting facilitation skills and ability to lead cross-functional teams that include executive and senior management without direct authority.
  • Financial management knowledge required.
  • Rare Disease experience required.
  • Excellent interpersonal, organizational, written and verbal communication skills.
  • Independent, motivated, team leader with the ability to thrive in a matrix environment.
  • Ability to support multiple asset teams simultaneously with strong organizational and time management skills and attention to detail.
  • Ability to accommodate and lead teams through shifting priorities, demands and timelines.
  • Ability to elicit cooperation from a wide variety of sources and to be persuasive, encouraging and motivating.
  • Adept at creating and communicating a clear vision for a program among team members to facilitate alignment of resources to achieve program and corporate goals.
  • Proven track record of implementing Project Management tools, methodologies, practices and infrastructure, as related to the biopharmaceutical Industry.
  • In-depth knowledge and skill with Microsoft (MS) suite including MS PowerPoint, MS Project, MS Word, MS Excel.
Responsibilities
  • Lead Asset Strategy Teams (ASTs) for Rare Disease Franchise by driving the teams to execute on the strategic vision of the Rare Disease portfolio.
  • Drive planning for key drug development stage-gate decision points after Phase 1 and co-chair stage-gate committee for Rare Disease franchise.
  • Manages an integrated program budget and resource plan in partnership with Finance team member and functional line representatives and sub-teams.
  • Facilitate resource planning, including financial and capacity assessments for Rare Disease franchise.
  • Partner with Strategic Product Planning function to establish or update Target Product Profiles (TPPs) for the Rare Disease portfolio that are aligned with the Strategic Value Proposition for the initial development and life-cycle management of the asset.
  • Coordinate formation of the ASTs for Rare Disease Franchise programs following a Go to Phase 2 (POC) decision at Stage Gate 3 and knowledge transfer from the Early-Stage AST members or Alliance Delivery Teams (ADTs) for partnered programs.
  • Collaborate with Research and Development (R&D) Operations team to ensure development team plans and timelines align with the strategic goals for the portfolio.
  • Ensure clear translation of the Strategic Value Proposition for each asset into an integrated strategic development plan for each program.
  • Proactively communicate contract milestones, scientific and financial obligations to ASTs for partnered programs to make well-informed strategic recommendations and decisions.
  • Proactively conduct risk management, and contingency and scenario planning across disciplines, ensure transparent communication of risks and escalate to executive management with appropriate speed.
  • Lead and facilitate decision analysis with the team including development and assessment of outcome scenarios with alternative development options, robust go/no go decision criteria, probability of technical and regulatory success (PTRS), and value and investment implications.
  • Ensure a coordinated approach across portfolio managers to ensure aligned execution and consistent reporting across stakeholders (ie, financial planning and analytics, executive leadership team and board of directors).
  • Other duties as assigned.
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Company Stage

Acquired

Total Funding

$813.4M

Headquarters

Dallas, Texas

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's launch of Magnolia's Guide to Adventuring showcases their innovative approach to raising disease awareness and redefining perceptions of Rett syndrome.
  • The acceptance of trofinetide for priority review by Health Canada could lead to significant market expansion and first-mover advantage in treating Rett syndrome in Canada.
  • The appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development, signals a strong commitment to advancing their R&D capabilities.

What critics are saying

  • The failure of the Phase III ADVANCE-2 trial for pimavanserin in schizophrenia highlights the high-risk nature of drug development in the biopharmaceutical sector.
  • Dependence on regulatory approvals, such as the FDA and Health Canada, introduces uncertainty and potential delays in bringing therapies to market.

What makes Acadia Pharmaceuticals unique

  • Acadia Pharmaceuticals focuses exclusively on neurological disorders, setting it apart from competitors with broader therapeutic areas.
  • Their commitment to corporate social responsibility, including initiatives like the Rett Sibling Scholarship, enhances their reputation and community engagement.
  • Acadia's strategic partnerships and corporate sponsorships amplify their research capabilities and market reach, distinguishing them from competitors who may not leverage such collaborations.

Help us improve and share your feedback! Did you find this helpful?